GLI1 and cancer: An alternative, intriguing hypothesis points to the existence of noncanonical, compensatory signal pathways that drive SMO-independent GLI1 activation in cancer, thus bypassing the inhibitory activity of SMO antagonists and hence contributing to the acquisition of resistance.